Pharsight announced that it has named five universities as Phoenix Centers of Excellence as part of its continuing collaboration with academic departments and research organizations worldwide. The Phoenix Centers of Excellence Program is a collaboration with Pharsight to enhance research and training in pharmacometrics at several academic centers. More than 350 pharmacy and medical schools worldwide currently usePharsight software for teaching and research purposes.
The five Pharsight Phoenix Centers of Excellence are:
• The University of Auckland School of Medicine, Department of Pharmacology and Clinical Pharmacology.
• The State University of New York (SUNY) at Buffalo School of Pharmacyand Pharmaceutical Sciences, Department of Pharmaceutical Sciences.
• The University of Minnesota School of Pharmacy, Department of Experimental and Clinical Pharmacology.
• Uppsala University Faculty of Pharmacy, Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy.
• The University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics.
The Centers of Excellence will collaborate with Pharsight to promote excellence in pharmacometrics through topical lectures and webinars on the application of model-based approaches to improve drug development knowledge and decisionmaking. The Centers of Excellence will also participate in other activities designed to recognize important contributions to the field of pharmacometrics through expanded access to Pharsight software, including Phoenix®, Pharsight’s desktop software platform for pharmacokinetic and pharmacodynamic (PKPD) data analysis and modeling.
“Our deeper collaboration with these top academic centers will support their pivotal role in the training of tomorrow’s pharmacometrics practitioners, of which there is a widely recognized global shortage. We are pleased to share Pharsight’s tools with these institutions and look forward to further collaborations to strengthen the interdisciplinary field of model-based drug development,"said Daniel Weiner, Ph.D., Senior Vice President and Chief Technology Officer of Pharsight.